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Lipid peroxidation causes 
endosomal antigen release for 
cross-presentation
Ilse Dingjan1, Daniëlle RJ Verboogen1, Laurent M Paardekooper1, Natalia H Revelo1, 
Simone P Sittig1, Linda J Visser1, Gabriele Fischer von Mollard2, Stefanie SV Henriet3, 
Carl G Figdor1, Martin ter Beest1 & Geert van den Bogaart1
Dendritic cells (DCs) present foreign antigen in major histocompatibility complex (MHC) class I 
molecules to cytotoxic T cells in a process called cross-presentation. An important step in this process is 
the release of antigen from the lumen of endosomes into the cytosol, but the mechanism of this step is 
still unclear. In this study, we show that reactive oxygen species (ROS) produced by the NADPH-oxidase 
complex NOX2 cause lipid peroxidation, a membrane disrupting chain-reaction, which in turn results in 
antigen leakage from endosomes. Antigen leakage and cross-presentation were inhibited by blocking 
ROS production or scavenging radicals and induced when using a ROS-generating photosensitizer. 
Endosomal antigen release was impaired in DCs from chronic granulomatous disease (CGD) patients 
with dysfunctional NOX2. Thus, NOX2 induces antigen release from endosomes for cross-presentation 
by direct oxidation of endosomal lipids. This constitutes a new cellular function for ROS in regulating 
immune responses against pathogens and cancer.
Dendritic cells (DCs) are antigen presenting cells of the immune system capable to activate naive T cells with 
exogenous antigen1–3. DCs constantly sample peripheral tissues for microbial pathogens and tumor cells that 
can be taken up by phago- or endocytosis. For activation of CD4 + T helper cells, these antigens are subse-
quently degraded in lysosomal compartments and presented in MHC class II. For activation of CD8 + cyto-
toxic T cells, exogenous antigens need to be presented in MHC class I in a process called cross-presentation. 
Cross-presentation can occur via a lysosomal and a cytosolic pathway. In the lysosomal pathway, antigen is 
degraded by lysosomal proteases and loaded in MHC class I in the lysosomal lumen. In the cytosolic pathway, 
antigen escapes from the endosomal lumen into the cytosol where it is processed by the proteasome for presenta-
tion in MHC class I1–4. Despite intensive research efforts, it is still unclear how antigen crosses the membrane of 
endosomes. The translocon Sec615–7 from the endoplasmic reticulum associated degradation (ERAD) pathway 
has been shown to transport proteins from endosomes into the cytosol, but the interpretations as well as func-
tional consequences of these studies were controversial1–3,8. This discussion was recently settled in an elegant 
study where they showed that the trapping of Sec61 in the endoplasmic reticulum with a single chain antibody 
blocked the release of antigen from endosomes and impaired cross-presentation8. However, this may not suffice 
to explain how large, folded and/or posttranslationally modified proteins as well as nucleic acids and dextrans are 
released from endosomes3,9 and, as also acknowledged in the study by Zehner et al.8, likely other pathways exist 
by which antigen is released from endosomes.
Antigen cross-presentation is promoted by the activity of the NADPH oxidase NOX210–14. Already within 
30 minutes after antigen uptake, NOX2 generates superoxide anions in the endosomal lumen in DCs and this 
production is sustained over the course of hours10–16. Superoxide anions react with protons resulting in the 
formation of H2O2 and alkalinization of the endosomal lumen. Thereby, NOX2 counteracts the activity of the 
V-ATPase and this inhibits the activation of lysosomal proteases with low pH optima, hence preserving the anti-
gen for cross-presentation10–12. H2O2 and other reactive oxygen species (ROS) produced by NOX2 activity can 
also oxidatively inactivate cystein cathepsins, which further inhibits degradation of antigen in endosomes of 
1Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical 
Center, Nijmegen, 6525 GA, the Netherlands. 2Department of Chemistry, Bielefeld University, Bielefeld, 33501, 
Germany. 3Department of Pediatrics, Radboud University Medical Center, Nijmegen, 6525 GA, the Netherlands. 
Correspondence and requests for materials should be addressed to G.v.d.B. (email: Geert.vandenBogaart@
RadboudUMC.nl)
Received: 09 July 2015
Accepted: 05 February 2016
Published: 24 February 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:22064 | DOI: 10.1038/srep22064
Figure 1. NOX2-produced ROS cause endosomal lipid peroxidation. (a) H2O2 production by DCs cultured 
in absence (no LPS; blue curve) or presence of LPS (+ LPS; black) measured with Amplex Red. (b) Sensor 
Bodipy581/591-C11 (structure) increases fluorescence at 510 nm upon peroxidation. Histograms show 
fluorescence intensity distributions from a typical experiment of DCs labeled with Bodipy581/591-C11 and 
incubation with LPS for the times indicated. (c–d) The mean fluorescence intensities (MFI) measured by flow 
cytometry of DCs cultured for 60 min with Bodipy581/591-C11 in presence or absence of LPS (c), or with LPS 
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DCs14,16,17. ROS also react with membranes and can oxidize membrane proteins, cholesterol and particularly 
(poly)unsaturated lipids in a process called lipid peroxidation18. Lipid peroxidation is a self-propagating chain 
reaction that proceeds very effectively, especially since oxygen is an apolar molecule which accumulates ~5-fold 
in lipid membranes compared to the aqueous environment19. Oxidized lipids have peroxide or aldehyde groups 
in their lipid tails, are more polar and can be shorter in length. As a consequence, lipid peroxidation is a destruc-
tive process, which is well-understood for over four decades to cause leakage of artificial and cellular membranes 
(see20–22 and references therein). Whereas leakage of endo/lysosomal contents to the cytosol may trigger cell 
death, this does not necessarily has to be the case3 and endosomal disruption is actually a widespread approach 
in the gene therapy research field for cellular delivery of nucleic acids23–26. In fact, endosomal disruption can be 
an efficient way to introduce antigen into the MHC class I pathway9,27,28. Therefore, we hypothesized that the sus-
tained ROS produced in endosomes by NOX2 would directly cause release of antigens into the cytosol via lipid 
peroxidation-induced membrane destabilization.
Results
NOX2-produced ROS cause endosomal lipid peroxidation. We first verified that ROS produced by 
NOX2 could trigger lipid peroxidation. We activated DCs with the TLR4-ligand LPS, which is well known to 
induce NOX2 activity29,30, resulting in an increase in ROS production (Fig. 1a). ROS can cause lipid peroxida-
tion, which can be measured with the Bodipy581/591-C11 probe. Bodipy581/591-C11 contains alkene groups 
mimicking unsaturated fatty acids and making it susceptible to peroxidation31. This probe incorporates into cel-
lular membranes and peroxidation causes a blue-shift of its fluorescence over time, which can be measured by 
flow cytometry (Fig. 1b). Directly oxidizing lipids with cumene hydroperoxide as a positive control resulted in a 
> 3-fold increase of the blue fluorescence. Culturing the cells in the presence of LPS resulted in a ~50% increase 
in Bodipy581/591-C11 fluorescence (Fig. 1c) supporting a role for NOX2 in lipid peroxidation. Indeed, inhi-
bition of NOX2 with the inhibitor phenylarsine oxide (PAO) decreased lipid peroxidation (Fig. 1d), although 
this compound is not specific for NOX2 as it oxidizes all vicinal thiols. We could not use the (more specific) 
NOX2-inhibitor diphenyleneiodonium (DPI), as this compound was too toxic for our DCs. To confirm the role 
of NOX2-produced ROS in lipid peroxidation, we measured peroxidation in human DCs which were siRNA 
silenced (RNAi) for gp91phox, one of the membrane components of NOX2 (NOX2KD; 94% knock-down effi-
ciency; Fig. 1e)32. In NOX2KD DCs, we found a ~25% reduction of Bodipy581/591-C11 signal (Fig. 1f), which was 
significant but relatively small, likely due to residual NOX activity15. These data indicate that NOX2 can induce 
lipid peroxidation in DCs.
To further confirm the role of ROS in lipid peroxidation, we used vitamin E. Vitamin E is a group of lipid sol-
uble antioxidants that selectively block lipid peroxidation by scavenging free electrons18. In agreement, the most 
active form of vitamin E, α -tocopherol, decreased peroxidation of Bodipy581/591-C11 by ~50% (Fig. 1d). We 
did not expect that α -Tocopherol affects endosomal alkanization by sequestering ROS in the endosomal lumen, 
because it predominantly incorporates in membranes. This was confirmed by experiments with the pH-sensitive 
fluorophores SNARF-1 conjugated to dextran and pHrodo-Green conjugated to OVA (Suppl. Fig. 1; compare to 
ref. 13). We also performed the Bodipy581/591-C11 assay with mouse bone marrow-derived DCs (BMDCs) in 
combination with α -tocopherol treatment. Similar to human DCs, lipid peroxidation in BMDCs was decreased 
after α -tocopherol treatment (Fig. 1g). Immunostaining human DCs for gp91phox showed that NOX2 localized 
to the peripheral cell membrane and to endosomal compartments (Fig. 1h), suggesting that substantial peroxida-
tion occurred in endosomal membranes. To address this, we employed the linoleamide alkyne (LAA) assay, where 
LPS-activated DCs were cultured in the presence of LAA which incorporates in cellular membranes. Peroxidation 
of LAA produces reactive aldehydes that indiscriminately bind to proteins and these modified proteins can be 
detected with Alexa fluor 448 azide (click chemistry)33. By pre-exposing the cells with OVA conjugated to Alexa 
fluor 647, we could distinguish peroxidation of endosomal membranes from membranes of other organelles 
(Fig. 1i). Indeed, endosomes (containing Alexa fluor 647-labeled OVA) were ~20% more peroxidated than other 
cellular membranes (Fig. 1j). Moreover, activating the cells with LPS increased lipid peroxidation in endosomal 
membranes ~1.7-fold (Fig. 1k) and peroxidation could again be inhibited with α -tocopherol (Fig. 1l), in accord-
ance with our results with Bodipy581/591-C11 and further supporting a role for NOX2 in lipid peroxidation in 
endosomes of DCs. We then determined whether NOX2-induced lipid peroxidation could cause the release of 
antigen from endosomes.
in absence (Ctrl) or presence of α -tocopherol (α -Toc) or phenylarsine oxide (PAO) (d). (e) Quantification of 
knock-down efficiency for gp91phox (NOX2KD) by Western blot (NT: non-targeting siRNA; GAPDH: loading 
control). (f) Similar to c, but now for NOX2KD DCs. (g) Similar to d, but now for mouse BMDCs. (h) Confocal 
microscope images of DCs stained for gp91phox (green) after treatment with OVA conjugated with Alexa fluor 
647 (OVA-AF647; red). (i) Detection of peroxidation-modified proteins on endosomes. DCs were incubated 
with OVA-AF647 and linoleamide alkyne (LAA). After incubation, cells were fixed and stained with Alexa 
fluor 488 azide (LAA-AF488). The fluorescence threshold was set on the OVA-AF647 channel and the green 
fluorescence was quantified. BF: bright field. (j) Difference between green fluorescence of the whole cell and the 
fluorescence thresholded on OVA-AF647. (k) LAA assay for DCs cultured in the absence or presence of LPS. 
LAA-AF488 signal was quantified for at least 10 cells. (l) Same as panel (k), but now for LPS-treated DCs in the 
absence or presence of α -Toc. Results show individual results for at least 3 donors/mice. Results from the same 
donor/mouse are connected by a black line. Scale bars, 10 μ m.
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Lipid peroxidation causes antigen release from endosomes. We confirmed that lipid peroxidation 
could cause leakage of artificial membranes by measuring ROS-induced leakage of the 14 kDa model protein 
lysozyme from 400 nm-sized liposomes composed of (poly)unsaturated phospholipids. These liposomes were 
exposed to a combination of H2O2 and iron, which causes formation of hydroxyl radicals, lipid peroxidation and 
membrane leakage18. Leakage of lysozyme from the liposomes makes it accessible for trypsin digestion and the 
Figure 2. Lipid peroxidation causes antigen release from endosomes. (a) Liposomes with lysozyme 
encapsulated were treated with a combination of H2O2 and Fe(II)SO4 (ROS) or Triton X-100 (TX100; positive 
control) followed by incubation with trypsin. Samples were analyzed by SDS-PAGE. Graph shows semi-
quantifications of band intensities from 4 independent experiments (mean ± S.E.M). (b) Scheme and confocal 
microscope images of a CCF4 assay. The cytosolic FRET probe CCF4 was cleaved by exogenous β -lactamase 
(β -lac) resulting in a decreased ratio of fluorescein (acceptor fluorophore; green) over coumarin (donor; blue) 
fluorescence. BF: bright field. (c–d) CCF4 cleavage efficiencies for DCs cultured in the absence or presence of 
LPS or α -tocopherol (α -Toc) (c) and for NOX2KD DCs (d). NT: non-targeting siRNA. (e–f) Cell viability by the 
MTT assay of cells cultured with exogenous cytochrome C (Cyt C) and in presence or absence of α -tocopherol 
(α -Toc) (e) as well as for NOX2KD DCs (f). Each donor is plotted in a different color. (g) Confocal micrographs 
of an unstimulated (no LPS) and stimulated (+ LPS) DC expressing galectin-3-mAzami (green), incubated 
with OVA conjugated to Alexa fluor 647 (OVA-AF647; red). (h) Fluorescence intensities of galectin-3-mAzami 
thresholded on OVA-AF647, relative to cytosolic fluorescence intensity, in DCs in the presence or absence of 
LPS and α -Toc. Results show individual results for at least 3 donors. Scale bars, 10 μ m.
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fraction of digested lysozyme hence correlates with liposome leakage. In agreement, the combination of H2O2 and 
iron caused leakage of lysozyme (~60%) as compared to the negative control in absence of ROS and the positive 
control with complete rupture of the liposomes by the detergent Triton X-100 (Fig. 2a). These results confirm 
the well-established notion that ROS-induced lipid peroxidation can trigger membrane leakage20–22. We then 
addressed whether NOX2-induced lipid peroxidation would also cause endosomal leakage in DCs.
Leakage of proteins from endosomes into the cytosol was measured by three assays. The first assay is based on 
the FRET sensor coumarin-cephalosporin-fluorescein (4)-acetoxymethyl (CCF4-AM)4,8. This probe accumulates 
in the cell and can be cleaved by the enzyme β -lactamase, which results in a loss of FRET between its coumarin 
(donor) and fluorescein (acceptor) fluorophores. We observed both CCF4 signal uniformly distributed in the cells 
and in punctate structures, indicating that CCF4 (and its cleavage products) localized partly in the cytosol and 
partly in intracellular compartments. Mammalian cells do not produce β -lactamase, but exogenous β -lactamase 
can be taken up by DCs and cleave CCF4 after β -lactamase escapes from endosomes into the cytosol or, con-
versely, after CCF4 influx into endosomes (Fig. 2b). CCF4 cleavage was promoted by activating the DCs with 
LPS, but could be blocked by the presence of α -tocopherol during β -lactamase uptake (Fig. 2c), demonstrating 
a role for lipid peroxidation in β -lactamase release from endosomes. α -Tocopherol protects cellular membranes 
from ROS-induced damage, not only by scavenging radicals, but also by promoting a negative curvature34. CCF4 
cleavage was significantly reduced in human NOX2KD DCs compared to controls (Fig. 2d). We could not perform 
endosomal leakage experiments with PAO, as this compound blocks endocytosis (Suppl. Fig. 2). Uptake was nei-
ther affected by α -tocopherol nor by knockdown of NOX2.
The second antigen leakage assay is based on the induction of apoptosis by exogenous cytochrome C. The 
presence of cytochrome C in the cytosol initiates apoptotic protease-activating factor 1 (Apaf-1) dependent apop-
tosis4,8,35. Leakage of exogenous cytochrome C from endosomes results in reduced cell viability, which can be 
measured by the MTT assay. α -Tocopherol was able to block cytochrome C-induced cell death, in accordance 
with our results with the CCF4 assay, supporting a role for NOX2-induced lipid peroxidation in cytochrome C 
escape from endosomes (Fig. 2e). RNAi knock-down of NOX2 even increased viability (compared to control cells 
without cytochrome C), which we attribute to reduced cell-damaging effects of ROS (Fig. 2f).
The third antigen leakage assay is based on the recruitment of galectin-3 to β -galactoside sugars, which are 
present on glycosylated proteins on the luminal, but not the cytosolic, side of endosomal membranes. In cells with 
intact endosomes, heterologously expressed galectin-3 tagged with the fluorescent protein mAzami is uniformly 
distributed in the cytosol of cells, but it clusters when it gains access to glycosylated moieties upon endosomal dis-
ruption36–38. As expected, LPS stimulation of DCs transfected with galectin-3-mAzami promoted the recruitment 
of galectin-3 to OVA-positive endosomes (Fig. 2g) and this could be blocked by inhibiting lipid peroxidation with 
α -tocopherol (Fig. 2h). Based on these data, we conclude that NOX2-induced lipid peroxidation can cause escape 
of antigen from endosomes into the cytosol.
Lipid peroxidation promotes cross-presentation. Next, we addressed whether endosomal anti-
gen escape by lipid peroxidation promotes antigen cross-presentation with use of two assays. We first used a 
well-established assay to measure cross-presentation based on the loading of DCs with part of the tumor antigen 
Figure 3. Lipid peroxidation promotes cross-presentation. (a) Scheme of the cytosolic and lysosomal 
pathways leading to antigen cross-presentation. (b) Time line of the Jurkat T cell activation assay with DCs 
presenting gp100. (c) Jurkat T cell activation assay with DCs incubated with α -tocopherol (α -Toc), MG132 
or lactacystin and with NOX2KD DCs after incubation with long (residues 272–300) or short peptide (residues 
280–288). On the y-axes the percentages of CD69-positive T cells for long (residues 272–300) over short peptide 
are depicted. (d) B3Z T cell activation assay with BMDCs incubated with α -tocopherol (α -Toc) after incubation 
with complete OVA protein or OVA peptide (SIINFEKL). On the y-axis the percentages of β -galactosidase 
producing T cells for OVA protein over OVA peptide. Results show individual results for at least 3 donors. Raw 
FACS data, and full short and long peptide T cell activation controls are in Suppl. Figs 3 and 4.
www.nature.com/scientificreports/
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gp100 (residues 272–300; long peptide)13,39,40. A smaller fragment of this long peptide (residues 280–288; short 
peptide) can be derived by lysosomal proteases (lysosomal pathway) or by the proteasome (cytosolic pathway) 
and cross-presented to a Jurkat T cell line heterologously expressing a receptor specific for MHC class I (HLA-A2) 
carrying gp100 short peptide (Fig. 3a). Upon activation of this receptor, these Jurkat T cells increase expression 
of the activation marker CD69 on their cell surface, which can be measured by flow cytometry (Fig. 3b and 
Suppl. Fig. 3a). Under our experimental conditions, the maximum percentage of activated Jurkat T cells was 
~55%, as determined by incubating DCs with an excess of short peptide that can exchange with endogenous 
peptide in MHC class I (Suppl. Fig. 3b–d). Importantly, the Jurkat T cell assay provides a direct measure for 
cross-presentation as Jurkat activation is independent of the co-stimulatory factors that are required for activation 
of naive T cells (e.g. CD80, CD86, IL-12, IFNγ ).
We started by confirming the known role of NOX2 in promoting cross-presentation10,11,13,14,41. The activa-
tion of Jurkat T-cells by NOX2KD DCs was significantly reduced by ~20% compared to control, similar to the 
inhibitions that we observed by treatment with the proteasome inhibitors MG132 and lactacystin (Fig. 3c). As 
antigens such as gp100 can be cross-presented via both proteasome-dependent (i.e. cytosolic) and -independent 
(i.e. lysosomal) pathways42, our results indicate that, under our experimental conditions, about 20% of gp100 
is cross-presented via the cytosolic pathway and that this pathway depends on NOX2. Importantly, selectively 
inhibiting lipid peroxidation with α -tocopherol during antigen uptake by DCs also significantly reduced Jurkat 
T cell activation (Fig. 3c).
As a second assay for cross-presentation, we performed a T cell activation assay with mouse BMDCs 
loaded with the model antigen OVA. OVA can also be partly processed in the cytosol by the proteasome and 
cross-presented in MHC class I to B3Z cells expressing a specific T cell receptor4,10,11,41. Engagement of this recep-
tor results in the production of β -galactosidase by these B3Z cells, which can be measured by colorimetric assays 
(Suppl. Fig. 4a). Similar to the Jurkat T cell assay, B3Z cells allow to directly measure cross-presentation as B3Z acti-
vation is independent of the co-stimulatory factors that are required for activation of naive T cells. In accordance 
with our results from the gp100 assay with human DCs, α -tocopherol treatment decreased activation of B3Z cells 
by ∼ 25% using OVA (Fig. 3d) and this was not changed using the specific OVA antigenic peptide (Suppl. Fig. 4b). 
We were not able to perform the B3Z assay in combination with MG132 and lactacystein due to high toxicity of 
these proteasome inhibitors (Suppl. Fig. 4c). These data are in accordance with our hypothesis that lipid peroxi-
dation triggers endosomal antigen release and this promotes cross-presentation. We then performed optogenetic 
experiments to more directly confirm this causal relationship.
Light-triggering lipid peroxidation causes antigen release. We developed an optogenetic approach 
to light-trigger lipid peroxidation specifically in endosomes of DCs. This system is based on the fluorescent pro-
tein KillerRed, which generates singlet oxygen and superoxide anion radicals upon exposure to orange light (at 
590 nm)43. KillerRed was targeted to the antigen processing compartment by genetic fusion to the endosomal 
SNARE protein VAMP8 (Fig. 4a), which traffics gp91phox to phagosomes41. DCs expressing VAMP8-KillerRed 
were exposed to light by culturing directly under an orange LED array. These exposure conditions did not result 
in decreased DC viability, but did result in an almost 2-fold increased lipid peroxidation in endosomes com-
pared to unexposed cells and to cells without expression of KillerRed as determined by the LAA assay (Fig. 4b). 
We could not use the Bodipy581/591-C11 assay in these experiments, because of spectral overlap of this probe 
with KillerRed. As expected, KillerRed activation also resulted in more antigen leakage from endosomes, as we 
observed an almost 2-fold increase of CCF4 cleavage efficiency compared to unexposed cells and to cells without 
expression of KillerRed (Fig. 4c). In these LAA and CCF4 experiments, we identified KillerRed-positive cells by 
residual (i.e. unbleached) fluorescence. Lipid peroxidation and the release of antigen upon VAMP8-KillerRed 
exposure was not specific for immune cells, as we observed similar results with the embryonic kidney cell line 
HEK293T (Fig. 4d–e) and with the human melanoma cell line MEL624. Although HEK293T cells are HLA-A2 
positive44, we did not observe cross-presentation by these cells with the Jurkat T cell assay, perhaps because of a 
lack of components required for subsequent antigen processing, such as the immunoproteasome45,46. Together, 
these data prove that lipid peroxidation causes antigen leakage from endosomes.
Endosomal antigen leakage is reduced in CGD patients. In the final set of experiments, we measured 
endosomal leakage in DCs isolated from blood of patients suffering from chronic granulomatous disease (CGD). 
CGD patients have a genetic mutation resulting in dysfunctional NOX2 and increased susceptibility to infectious 
diseases15. Cross-presentation is also impaired in DCs of CGD patients13,47 and this has been linked to the higher 
risk of developing autoimmune diseases48 and impaired antifungal protection47. We performed the CCF4 assay 
on DCs from three CGD patients with mutated p47phox (a cytosolic component of NOX2) and one patient with 
mutated membrane-bound gp91phox (Fig. 4f). In agreement with our experiments with NOX2KD, CCF4 cleavage 
was substantially reduced in DCs from CGD patients compared to healthy individuals (Fig. 4g), whereas control 
experiments with BSA conjugated to Alexa fluor 488 showed that antigen uptake was not changed significantly 
(Fig. 4h). This result demonstrates that release of antigen from endosomes is impaired in CGD patients, further 
supporting a role of NOX2 in this process.
Discussion
The pivotal role of NOX2 in facilitating cross-presentation is well-established10–14,41. Although it is clear that 
NOX2 preserves antigen by inhibiting endo/lysosomal proteases via oxidation14,16,17 and delayed acidification10–12, 
the direct mechanistic link between NOX2-produced ROS and cross-presentation was unclear13. We now show 
that NOX2-produced ROS induce lipid peroxidation in endosomal membranes and thereby can cause antigen 
leakage from the endosomal lumen into the cytosol (Fig. 4i). These findings are in line with the reduced lipid 
peroxidation observed upon inhibition of NOX2 in murine neurons and microglia49 and with the role of ROS 
www.nature.com/scientificreports/
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Figure 4. Direct induction of endosomal antigen release and impaired release in CGD. (a) Confocal 
micrographs of a DC expressing VAMP8-KillerRed (green) and incubated with OVA conjugated to Alexa fluor 
647 (OVA-AF647; red). BF: bright field. Scale bar, 10 μ m. (b) Linoleamide alkyne lipid peroxidation assay as in 
fig. 1i, but now for exposed or non-exposed DCs with or without expression of KillerRed. (c) CCF4 endosomal 
antigen leakage assay as in fig. 2b, but now for exposed or non-exposed DCs with or without expression of 
KillerRed. (d–e) Similar as panels (b,c) but now for HEK293T cells. (f) p47phox and gp91phox expression in 
www.nature.com/scientificreports/
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in cathepsin release from lysosomes50,51. Our findings explain how neutrophils, which have very high NOX2 
activity during the oxidative burst, can be efficient antigen cross-presenting cells52. Our findings also corroborate 
the suggestion that cross-presentation is facilitated by pathogens that actively disrupt the phagosomes of their 
host-cells53. This disruption allows the microbes access to nutrients from the cytosol of the host cell and this is 
required for their replication, but could also enable their detection by the immune system.
Our study also provides a new mechanistic link of the well-established positive correlation between 
cross-presentation and autophagy54. NOX2-generated ROS are necessary for the induction of autophagy by pha-
gosomal recruitment of the autophagy protein LC355,56. This LC3 recruitment is compromised in CGD patients 
resulting in autophagic defects, which underlie the pathogenesis of granulomatous colitis56. The recruitment of 
LC3 to phagosomes can be blocked with α -tocopherol55, suggesting the involvement of intracellular scavenger 
receptors that recognize endosomal products of lipid peroxidation. Our results now show that at this point the 
integrity of the phagosomal membrane can be compromised, resulting in the leakage of antigen into the cytosolic 
MHC class I pathway and hence promoting cross-presentation.
Another topic of intense study is the role of ROS in cancer and inflammation57. ROS are well-known to act 
as secondary messengers for activation of immune cells58 and regulate for instance T cell activation by DCs59. In 
this study, we have identified an additional mechanism of regulation of the immune function by ROS. Our results 
show that NOX2-induced ROS can cause lipid peroxidation, which in turn can result in release of (tumor) antigen 
into the cytosol, where it becomes accessible to the proteasome. Cross-presentation is hence facilitated by oxida-
tion of endosomal lipids and this is a new cellular role for ROS. As already suggested previously3,9,27, the aspecific 
leakage of endosomal compartments explains how large, folded and/or posttranslationally modified proteins 
as well as nucleic acids and dextrans can reach the cytosol. Thus, although our results do not exclude roles for 
specific protein channels such as Sec615–8, lipid peroxidation provides an, at least complementary, mechanism by 
which antigens escape from endosomes for cross-presentation by DCs.
The release of antigen from endosomes by lipid peroxidation may be used as a novel strategy to combat dis-
ease. Augmenting ROS specifically in endosomes or phagosomes of DCs by means of radical inducing molecules 
may help to evoke a CD8 + T cell response against cancer and infectious disease. Such an approach might well be 
feasible, given that the generation of ROS in endosomes of target cells is already exploited for delivery of siRNA 
in the gene therapy field23–26. Thus, our results underscore that approaches to target ROS in endosomes of antigen 
presenting cells might be a promising therapeutic strategy for cancer and (auto)immune diseases.
Methods
Cells and transfection. Human DCs were derived from peripheral blood monocytes (PBMCs) obtained 
from buffy coats of healthy individuals (informed consent obtained from all individuals) according to institu-
tional guidelines and as described previously60. Briefly, after purification on a Ficoll-gradient, monocytes were 
differentiated into immature DCs by culturing 6 days at 37 °C (5% CO2) in the presence of 300 U/ml IL-4 and 
450 U/ml granulocyte macrophage colony-stimulating factor (GM-CSF) in complete RPMI-1640 medium (Gibco 
by Thermo Fisher) containing 10% fetal bovine serum (FBS; Greiner Bio-one), 2 mM UltraGlutamine (Lonza) 
and 1% Antibiotic-Antimytotic (AA; Gibco by Thermo Fisher). CGD DCs were derived from PBMCs obtained 
from blood of three p47phox-/- and one gp91phox-/- patients61 using the same protocol. All CGD patients were 
between the age of 5 to 13 years and free from any infectious or inflammatory diseases. HEK293T cells were 
cultured in DMEM (Gibco by Thermo Fisher) containing 10% FBS, 1% non-essential amino acids and 0.5% AA. 
Jurkat E6.1 cells expressing CD8 + T cell receptors that recognize gp100-peptide(280–288) in the context of HLA-
A2 were used for the T cell activation assay with human DCs. They were cultured in RPMI-1640 containing 10% 
FBS, 2 mM UltraGlutamine and 0.5% AA.
Mouse bone marrow derived dendritic cells (BMDCs) were obtained from healthy C57BL/6 mice. BMDCs 
were differentiated by culturing 7 days in the presence of 20 ng/ml mouse GM-CSF in RPMI-1640 containing 10% 
FBS, 2 mM UltraGlutamine, 1% AA and 28 μ M β -mercaptoethanol. B3Z T cell hybridoma cells containing a lacZ 
construct inducible by activation of its T cell receptor specific for OVA peptide in the context of H-2 Kb62 were 
used for the T cell activation assay with BMDCs. B3Z cells were cultured in the presence of 1 mM hygromycin 
B in IMDM containing 5% FBS, 2 mM UltraGlutamine, 1% AA and 28 μ M β -mercaptoethanol. All experiments 
with human samples were conducted in accordance with the relevant guidelines. Patient tissue and samples were 
obtained in accordance with the Declaration of Helsinki and approved consent was obtained from all patients 
or their legal representatives. All experiments were approved by the ethics committee from Radboud University 
Medical Center.
For NOX2KD, DCs were electroporated with siRNA against NOX2 subunit gp91phox (CCGAGUCAA 
UAAUUCUGAUCCUUAU; Thermo Fisher) or with irrelevant ON-TARGET plus Non-Targeting (NT) siRNA#1 
(Dharmacon) using a Neon Transfection System (Thermo Fisher; 1,000 V, 40 ms, 2 pulses). After electroporation, 
lymphocytes from three p47phox-/- (CGD1-3; blue) and one gp91phox-/- (CGD4; green) CGD patients 
by Western blot (GAPDH: loading control). (g) CCF4 endosomal antigen release assay as in fig. 2b, but 
now with DCs derived from monocytes from the CGD patients from panel (d) (Ctrl: DCs from healthy 
donors). (h) Uptake of BSA conjugated to Alexa fluor 488 (BSA-AF488) by DCs of CGD patients, 
presented as percentage BSA-AF488-positive cells and MFI. Results show individual results of at least 
3 donors/experiments. (i) Model scheme of NOX2-induced antigen leakage from endosomes. Superoxide 
anions produced by NOX2 and protons provided by the V-ATPase form H2O2 and hydroxyl radicals (Fenton 
reaction). These ROS induce lipid peroxidation, which disrupts endosomal membranes and causes the release 
of antigen (purple spheres) into the cytosol.
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cells were transferred to serum-free RPMI medium without AA and phenol red. After 3 hours, this medium 
was replaced by complete RPMI medium and cells were cultured for 48 hours to achieve maximal knock-down, 
as judged by Western analysis. Proteins were detected with mouse monoclonal antibody anti-NOX2/gp91phox 
(ab80897, Abcam) and rabbit polyclonal antibody anti-p47phox (sc-14015, Santa Cruz) (all at 1:500 dilution 
(v/v)) in combination with goat anti-rabbit or goat anti-mouse conjugated with IRDye 680 or 800 (all LI-COR) as 
secondary antibodies (1:5,000 dilution (v/v)).
The construct coding for VAMP8-pKillerRed was made by standard cloning procedures. First mouse 
VAMP8 with restriction sites XhoI and BamHI was generated by PCR, cut and ligated into pmCherry-N1. 
Next, mCherry was replaced with KillerRed43 via BamHI/NotI restriction sites. KillerRed-N1 was a gift from 
Michael Davidson (Addgene plasmid # 54636). DCs were electroporated with the VAMP8-KillerRed construct 
as described63. HEK293T cells were transfected using lipofectamine (Thermo Fisher), following the procedures 
of the manufacturer. DCs and HEK293T cells were cultured for 16 hours to achieve highest expression levels of 
VAMP8-KillerRed. For exposure, DCs and HEK293T cells expressing VAMP8-KillerRed were cultured for 
0.5 – 4 hr directly under a 109 mW LED array at 590 nm (Thorlabs).
Lysozyme leakage assay. A mixture composed of 25 mg 1,2-dioleoyl-sn-glycero-3-phosphocholine, 
25 mg 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine, 5 mg DOPS 1,2-dioleoyl-sn-glycero-
3-phospho-L-serine and 5 mg cholesterol (all Avanti) in chloroform was dried in a stream of N2 followed by 
vacuum. After drying, lipids were resuspended in 1 ml PBS containing 5% (w/v) sodium cholate and 7 mg/ml 
lysozyme (from chicken egg white; Sigma). The emulsion was dialyzed (7 kDa MWCO) and extruded through 
a polycarbonate filter with 400 nm pore size. Non-encapsulated lysozyme was removed by gel filtration 
(Sephadex-G150). The liposomes were incubated with 200 mM H2O2 and 100 μ M freshly prepared Fe(II)SO4 
(Sigma) for 3 hours at room temperature (RT) followed by incubation with 50 mg/ml trypsin for 4 hours at 37 °C. 
Positive control experiments were performed with 0.2% Triton X-100. Samples were analyzed by 15% SDS-PAGE 
and stained with Coomassie Brilliant Blue R250 (CBB).
ROS and lipid peroxidation assays. For the Amplex Red assay, cells were incubated for 2–4 hours in a 96 
well plate (100,000 cells/well) in serum-free RPMI with 2.2 mM OVA (Sigma) and with or without 1 μ g/ml LPS 
(Sigma). After incubation, the medium was changed for RPMI without phenol red containing 50 μ M Amplex 
UltraRed reagent (Thermo Fisher) and 3 U/ml horseradish peroxidase (Sigma) and the fluorescence of resofurin 
was measured every 15 minutes for 2 hours of subsequent incubation.
For the Bodipy581/591-C11 assay, DCs were loaded with 2.2 mM OVA and cultured in the presence of 1 μ M 
Bodipy581/591-C11 (4,4-difluoro-5-(4-phenyl-1,3-butadienyl)-4-bora-3a,4a-diaza-s-indacene-3-undecanoic 
acid; Thermo Fisher) in serum-free RPMI for 60 minutes at RT. 1 μ g/ml LPS, 100 μ M α -tocopherol (Sigma) and/
or 1 μ M phenylarsine oxide (PAO, Sigma) were added together with Bodipy581/591-C11. After incubation, the 
Bodipy581/591-C11 fluorescence was measured by flow cytometry (excitation: 488 nm; emission: 530/30 nm; 
FACSCaliber, BD biosciences). The signal before incubation was subtracted for background correction.
The LAA Click chemistry experiments were performed following the manufactures protocol (C10445, 
Thermo Fisher) with some modifications. DCs were loaded with 55.5 μ M OVA-Alexa fluor 647 and 1 μ g/ml LPS 
as adjuvant and cultured in the presence of 50 μ M Click-iT LAA solution and 100 μ M α -tocopherol in serum-free 
RPMI for 1 hour at 37 °C on 12 mm coverslips in 24 wells plates. KillerRed-transfected DCs were exposed during 
incubation as described above. After culturing, the cells were washed, fixed with 4% PFA, permeabilized with 
0.5% TX100 and blocked with 1% BSA (all diluted in PBS and incubated at RT). Coverslips were incubated for 
30 minutes at RT protected from light with Click-iT reaction cocktail containing Cu(II)SO4 and Alexa fluor 488 
azide. Finally, the cells were washed and embedded in mounting medium containing 0.01% (v/v) Trolox and 68% 
(v/v) glycerol. Imaging was done with a Leica SP8 confocal microscope with a 63 × 1.20 NA water immersion 
objective. For analysis of the green fluorescent signal, the endosomes were identified by setting a threshold on the 
signal of the OVA-Alexa fluor 647 channel.
Antigen uptake and leakage assays. For the antigen uptake experiments, DCs were incubated with 
100 μ g/ml BSA-Alexa fluor 488 (Thermo Fisher) and 1 μ g/ml LPS for 60 minutes in the presence or absence 
of 500 μ M α -tocopherol or 1 μ M PAO. After washing the cells, the percentage of BSA-AF488 positive cells was 
measured by flow cytometry.
For the cytochrome C experiments35, DCs were incubated with 10 mg/ml cytochrome C (from equine heart; 
Sigma), 1 μ g/ml LPS and/or 500 μ M α -tocopherol in complete RPMI for 20 hours at 37 °C. After incubation, the 
medium was removed and 0.5 mg/ml MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was 
added to each sample. After 1–4 hours incubation, lysis buffer containing 90% iso-propanol, 0.0125% SDS and 4% 
1 M HCl was added and absorbance was measured at 595 nm to determine cell death.
The CCF4/β -lactamase assay36 was performed in Willco petri dishes according to the protocol of the manu-
facturer (K1095, Thermo Fisher). Briefly, DCs were incubated with 1 μ M Substrate Loading Solution, 1 μ g/ml LPS 
as adjuvant and if applicable 500 μ M α -tocopherol in Live Cell Imaging Medium (Thermo Fisher) for 90 minutes 
at 37 °C. After 90 minutes incubation time, DCs were washed and incubated with 1 mg/ml β -lactamase (Sigma). 
In addition, 1 μ g/ml LPS and/or 500 μ M α -tocopherol were included together with the β -lactamase if these were 
added during the first incubation step. The second incubation step was done in Live Cell Imaging Medium for 
3 hours at 37 °C. The KillerRed-transfected DCs were exposed or shielded from light during the last 30 minutes 
of incubation. Cells were washed again and imaged with a Leica SP8 confocal microscope and a 63 × 1.20 NA 
water immersion objective (405 nm excitation; 419–458 nm blue and 504–600 nm green emission of the coumarin 
donor and fluorescein acceptor fluorophores, respectively). The FRET efficiencies F were calculated as the ratio 
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of the green over the blue fluorescence intensities. The FRET efficiency of control cells in absence of β -lactamase 
Fneg was used as a negative control. The FRET cleavage C was then calculated as (Eqn 1):
( )= / . ( )–C F F F 1neg neg
For the galectin-3 experiments, galectin-3-mAzami was cloned from mAG-GAL338 into the NotI and PspOMI 
sites of pCDNA6-myc His B (Thermo Fisher). mAG-GAL3 was a gift from Niels Geijsen (Addgene plasmid # 
62734). DCs were transfected with galectin-3-mAzami, following the same procedure as for Vamp8-KillerRed. 
After electroporation, the DCs were cultured for 16 h on coverslips and subsequently incubated with OVA con-
jugated to Alexa fluor 647 for 1 h in the presence or absence of 1 μ g/ml LPS and/or 500 μ M α -tocopherol. After 
incubation, cells were fixed with 4% PFA and embedded in mounting medium containing 0.01% (v/v) Trolox and 
68% (v/v) glycerol. Imaging was done with a Leica DM6000 epi-fluorescence microscope fitted with a 63 × 1.40 
NA oil immersion objective and appropriate filters for mAzami (excitation: BP470/40; dichroic: LP495; emission: 
BP524/50) and Alexa fluor 647 (excitation: BP620/60; dichroic: LP660; emission: BP700/75). For analysis, the 
fluorescence intensities of galectin-3-mAzami from individual releasing endosomes, identified by the OVA-Alexa 
fluor 647 channel, were corrected for the cytosolic fluorescence intensities similar as described64.
pH measurements. For the labeling of OVA with pHrodo, a stock solution of 9 mM pHrodo Green STP ester 
(Thermo Fisher) in DMSO was mixed with 10 volumes of 10 mg/ml OVA and incubated for 2 h at RT. DCs were 
pulsed with 1 mM pHrodo-conjugated OVA and 1 μ g/ml LPS in the presence or absence of 500 μ M α -tocopherol 
for 15 minutes, followed by a chase of 150 minutes. The fluorescence intensities of pHrodo was measured by 
flow cytometry at 20, 40, 60, 90, 120 and 150 minutes after starting with the chase (excitation: 488 nm; emission: 
530/30 nm). pH was calibrated by measuring the fluorescence of pHrodo in a standard solution series of known 
pH.
For the SNARF-1 experiments, DCs adhered to glass bottom microdishes were washed and incubated 
for 30 minutes with 1 mg/ml SNARF-1 dextran 10,000 MW (D3303, Thermo Fisher) with or without 500 μ M 
α -tocopherol or 1 μ M PAO. DCs were imaged with a Leica SP8 confocal microscope and a 63 × 1.20 NA water 
immersion objective (540 nm excitation; 550–600 nm green and 620–700 nm red emission peaks of SNARF-1). 
The pH calibration curve was created by imaging SNARF-1 dextran-containing DCs that were incubated with 
buffers of different pH (10 mM phosphate buffer, 150 mM NaCl) and 0.003% Triton-X100.
Cross-presentation assays. For the human T cell activation assay, HLA-A2 positive DCs (70,000 cells/
well) were incubated for 1 hour at 37 °C in X-vivo medium (Lonza) containing 2% human serum in 96 wells plates. 
Cells were then washed and incubated with gp100 short peptide (10 μ M gp100(280–288); GenScript) or long 
peptide (100 μ M gp100(272–300); JPT) in combination with T cell receptor stimulation mix (4 μ g/ml R-848 and 
poly(I:C); Enzo Life Sciences) for 4 hours in X-vivo medium at 37 °C. If applicable 500 μ M α -tocopherol, 10 μ M 
MG132 (Sigma) or 10 μ M lactacystin (Sigma) were also added during this time step. The KillerRed-transfected 
DCs were exposed or shielded from light during antigen uptake. After incubation, cells were washed and resus-
pended in X-vivo medium containing Jurkat E6.1 cells (100,000 cells/well) carrying a specific T cell receptor 
recognizing HLA-A2 with gp100(280–288)65 and co-cultured for 18 hours at 37 °C. T cells were stained with 
α CD69-FITC (1:10, BD biosciences), α CD3-APC (1:10, eBiosciences) and 7AAD viability staining (1:14, 
Biolegend) or Propidium Iodide (PI; 0.5 μ g/ml) and analyzed with a FACSCalibur (BD biosciences). CD69 
expression to measure T cell activation was analyzed using FlowJo software and Prism 5. Briefly, cells were gated 
on viability (7AAD or PI), followed by gating for CD3 staining, and CD69 expression was measured. T cell acti-
vation was calculated as the ratio of CD69 positive cells stimulated with long over stimulation with short peptide.
For the T cells activation assay with mouse cells, BMDCs (from H-2 Kb positive C57BL/6 mice; 80,000 cells/
well) were incubated with 80 μ g/ml OVA protein, 5 ng/ml OVA peptide (residues 257–264; SIINFEKL), 1 μ g/ml 
LPS and if applicable 500 μ M α -tocopherol in complete RPMI-1640 for 30 minutes (OVA peptide) or 5 hours 
(OVA protein) at 37 °C. After incubation, cells were washed and incubated in complete RPMI-1640 containing 
B3Z cells (80,000 cells/well) for 18 hours. Supernatant was removed and cells were incubated with Z-buffer con-
taining 10 mM DTT (MP Biomedicals), 9 mM MgCl2, 0.15 mM CPRG (Calbiochem) and 0.125% NP40 (Sigma) 
for 1–5 hours at 37 °C. Absorbance was measured at 595 nm. Total T cell activation was calculated as the ratio 
of the absorbances of cells stimulated with the full-length OVA protein over stimulation with the OVA peptide.
Statistical analysis. All experiments were assessed using paired Student t tests, except for the data with 
CGD patient material where an unpaired Student t test was used. Two-sided P values < 0.05 were considered to 
be statistically significant (*p < 0.05, **p < 0.01, ***p < 0.001).
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